Renaissance Technologies LLC Boosts Stock Holdings in Encompass Health Co. (NYSE:EHC)

Renaissance Technologies LLC boosted its holdings in Encompass Health Co. (NYSE:EHC - Free Report) by 63.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,900 shares of the company's stock after buying an additional 19,700 shares during the period. Renaissance Technologies LLC owned approximately 0.05% of Encompass Health worth $4,701,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of EHC. MassMutual Private Wealth & Trust FSB raised its stake in shares of Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock valued at $27,000 after purchasing an additional 137 shares during the period. CBIZ Investment Advisory Services LLC boosted its position in shares of Encompass Health by 38.7% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock valued at $42,000 after acquiring an additional 127 shares during the period. Tompkins Financial Corp purchased a new stake in Encompass Health in the 4th quarter worth approximately $46,000. V Square Quantitative Management LLC boosted its holdings in Encompass Health by 43.8% in the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company's stock valued at $54,000 after purchasing an additional 177 shares during the period. Finally, Morse Asset Management Inc bought a new position in shares of Encompass Health in the third quarter worth $68,000. Institutional investors own 97.25% of the company's stock.

Insiders Place Their Bets

In other news, CAO Andrew L. Price sold 5,042 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the sale, the chief accounting officer now directly owns 69,164 shares of the company's stock, valued at $6,798,129.56. The trade was a 6.79 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.10% of the stock is owned by corporate insiders.

Encompass Health Trading Up 11.6 %

NYSE:EHC traded up $11.81 during midday trading on Friday, reaching $113.22. 1,263,881 shares of the stock traded hands, compared to its average volume of 676,290. The company has a fifty day moving average of $99.86 and a 200 day moving average of $98.37. Encompass Health Co. has a 12 month low of $81.45 and a 12 month high of $114.27. The stock has a market capitalization of $11.40 billion, a P/E ratio of 25.42, a PEG ratio of 2.31 and a beta of 0.87. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. On average, research analysts predict that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Tuesday, April 1st were given a dividend of $0.17 per share. The ex-dividend date was Tuesday, April 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.60%. Encompass Health's dividend payout ratio is presently 15.25%.

Wall Street Analyst Weigh In

EHC has been the subject of several recent analyst reports. Barclays boosted their target price on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research report on Friday. StockNews.com downgraded shares of Encompass Health from a "buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Royal Bank of Canada reissued an "outperform" rating and issued a $110.00 price target on shares of Encompass Health in a research note on Tuesday, February 11th. KeyCorp raised their price objective on shares of Encompass Health from $120.00 to $122.00 and gave the company an "overweight" rating in a research report on Friday. Finally, William Blair reiterated an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $109.11.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.